Let's transform cardiovascular care together
If you are an employer or payer looking for a comprehensive heart health enterprise solution, contact us.
Our Products
(855) 338-8800
MOUNTAIN VIEW, Calif., November 3, 2025 — GE HealthCare (Nasdaq: GEHC) and AliveCor announced the world’s first clinical go-live of the integration between GE HealthCare’s MUSE™ Cardiology Information System and AliveCor’s KardiaMobile® 6L electrocardiogram (ECG) device at Hannover Medical School (MHH), Germany. The collaboration aims to optimize patient care and reduce hospitalizations linked to cardiac events by expanding care outside the hospital with remote patient monitoring*.
“This is a major step forward in bringing cardiac rhythm care closer to the patient,” said Prof. Dr. David Duncker, Head of Hannover Heart Rhythm Center at Hannover Medical School. “By integrating remote ECG data into our clinical systems, we can improve diagnostic speed, reduce follow-up workload, and enhance coordination of care.”**
Patients can use KardiaMobile 6L to record medical-grade single-lead and six-lead ECGs from home or other remote locations, aiming to reduce the need for in-person hospital or clinic visits3. Through this clinical integration by MHH, these recordings are securely and seamlessly integrated into the hospital’s existing workflow through GE HealthCare’s MUSE Cardiology Information System. MHH physicians are able to access, evaluate, and compare KardiaMobile 6L ECGs and in-hospital and clinic ECGs in near real time***, supporting faster clinical decision-making and continuity of care, while also giving patients peace of mind that their physicians may have the opportunity to review their ECGs promptly.
With MUSE, ECGs acquired using KardiaMobile 6L are automatically routed into the electronic medical record at MHH, eliminating manual data entry and supporting efficiency gains. One study found that using KardiaMobile for remote patient monitoring reduces the need for in-person ECGs and other cardiac assessments, enabling clinicians to deliver care more efficiently without adding to their workload.3
KardiaMobile 6L is clinically validated to detect atrial fibrillation, and other arrhythmias—conditions associated with significant hospitalizations and mortality worldwide. Atrial fibrillation is now the most common sustained4 cardiac arrhythmia in Europe, affecting over 11 million people1 and contributing to 8.4 million disability-adjusted life years (DALYs) globally.2 By enabling patients to capture medical-grade ECGs from home or remote locations, the integration expands access to diagnostic data, supports decentralized care models, and may help reduce avoidable hospital visits.
The collaboration between GE HealthCare, Hannover Medical School and AliveCor underscores a shared commitment to advancing connected, patient-centric cardiac care. By combining mobility, precision, and interoperability, the collaboration helps clinicians deliver more timely, informed, and coordinated care.
“We at GE HealthCare are proud to highlight our collaboration with AliveCor and Medical School Hannover, which exemplifies the power of combining cutting-edge technology with visionary clinical leadership. Together, we are bringing our solutions that push the boundaries of what’s possible in healthcare—merging GE HealthCare and AliveCor’s technologies and deep expertise with MHH’s pioneering research and clinical aspirations. This collaboration reflects our shared commitment to innovation without limits, delivering meaningful impact for patients, providers, and the future of care,” said Balázs Pozsony, Cardiology General Manager International, GE HealthCare.
“We’re thrilled to join forces with GE HealthCare and Medical School Hannover, blending AI innovation, precision technology, and world-class research to reimagine cardiac care and move healthcare forward,” said Simona Esposito, SVP of Sales, Global Markets at AliveCor. “This partnership is about more than technology—it’s about making a real difference for patients, empowering providers, and expanding diagnostic capabilities across the cardiac care pathways.”
For more information on GE HealthCare’s MUSE NX and diagnostic cardiology solutions, visit https://www.gehealthcare.com/products/diagnostic-ecg/muse-nx.
To learn more about AliveCor, visit https://alivecor.com/
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
Media contacts
Lena Weissenbacher
Sr. Communications Manager, International Region
GE
HealthCare
+43 664 186 3301
olena.weissenbacher@gehealthcare.com
AliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) devices, is transforming cardiology with its medical-grade AI solutions. The company was named to the inaugural TIME World's Top Health Tech Companies 2025 list—recognition of its commitment to delivering innovative devices and services that empower patients and physicians with personalized, actionable heart data. With over 300 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L to detect 35 cardiac conditions (14 arrhythmias and 21 morphologies), was designed exclusively for use by healthcare providers. AliveCor's enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook.
Morgan Mathis
Director, Corporate Communications
AliveCor
mmathis863@alivecor.com
Source
1. Velleca M, Costa G, Goldstein L, Bishara M, Boo LM. A Review of the Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic across Europe. EMJ Cardiol. 2019;7(1):110-118. Available from: https://www.emjreviews.com/cardiology/article/a-review-of-the-burden-of-atrial-fibrillation-understanding-the-impact-of-the-new-millennium-epidemic-across-europe/
2. Global Burden of Disease Study 2019. Atrial fibrillation and flutter – Level 3 cause. The Lancet. Published online 2020. Available from: https://www.thelancet.com/pb-assets/Lancet/gbd/summaries/diseases/atrial-fibrillation.pdf
3. Lambert CT, Patel D, Bumgarner JM, et al. Atrial fibrillation future clinic. Novel platform to integrate smart device electrocardiogram into clinical practice. Cardiovascular Digital Health Journal. 2021. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8890049/
4. Zhou M, Wang H, Wang Z, Li Y, Li Y, Liu S. Global, regional and national burden of atrial fibrillation and its attributable risk factors from 1990 to 2019: Results from the Global Burden of Disease Study 2019. BMC Public Health. 2022;22:14403. Available from: https://doi.org/10.1186/s12889-022-14403-2
Disclaimer
*This product does not generate alarms or alerts for physicians related to ECG data sent from the remote location to the electronic medical record.
**The statements by GE HealthCare’s customers described here are based on his/her own opinions and on results that were achieved in his/her unique setting. Since there is no “typical” hospital/clinical setting and many variables exist, i.e., hospital size, case mix, staff expertise, etc., there can be no guarantee that others will achieve the same results.
***Actual time may vary slightly due to hospital network and processing times.
Let's transform cardiovascular care together
If you are an employer or payer looking for a comprehensive heart health enterprise solution, contact us.